Generic drugmaker Lupin Ltd announced that it had received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) of a critical inhaler drug.

In an exchange filing today, Lupin announced that it had received a nod from USFDA for Tiotropium Bromide Inhalation Powder in the strength of 18 mcg per capsule, a generic equivalent of Spiriva HandiHaler owned by Boehringer Ingelheim Pharmaceuticals that is indicated to reduce exacerbations in chronic obstructive pulmonary disease (COPD) patients.

According to the business, Lupin’s generic approval for Spiriva HandiHaler is the first in the US and the first dry powder inhalation medication from India for the US.

Furthermore, the company announced on Tuesday that its corporate social responsibility (CSR) arm, the Lupin Human Welfare and Research Foundation (LHWRF), has signed a Memorandum of Understanding (MoU) with the Maharashtra government to address the rising prevalence of Cardiovascular Diseases (CVD) and COPD in the Palghar district of Maharashtra.

Shares of Lupin rose to an intraday high of Rs 885.3, up 6.5% from the previous closing price. The stock closed at Rs 874.80 on June 21, 5.41% higher than the last day’s closing price. The average trading volumes on the counter jumped seven-fold today.